限制帕利珠单抗推荐对胎龄>29周婴儿呼吸道合胞病毒住院的影响:一项意大利多中心研究
本研究为在意大利北部三个新生儿重症监护病房开展的非干预性回顾性队列研究,纳入2015年3月15日至2017年3月14日间出生、胎龄29至35周的婴儿,比较意大利药品管理局(AIFA)2016年限制帕利珠单抗报销资格(将胎龄>29周婴儿排除在外)前后两个流行季(2015-2016季 vs 2016-2017季)的RSV住院(RSVH)发生率。632例合格婴儿中536例有数据(第1季262例、第2季274例)。总体RSVH在第1季和第2季分别为1.9%和5.1%(OR=2.77;95%CI 0.98-7.8,p=0.045);仅限未暴露于帕利珠单抗者,两季RSVH分别为1.8%和5.9%(OR=3.42;95%CI 0.96-12.20,p=0.045)。其他呼吸道病毒住院率两季无差异。作者认为,限制帕利珠单抗报销资格导致RSVH显著增加,未来帕利珠单抗处方与报销规则决策应基于对成本效益比的审慎评估。
要点
- AIFA 2016年将帕利珠单抗报销限制为RSVH高风险婴儿,胎龄>29周婴儿被排除在报销之外。
- 总体RSVH第1季(限制前)1.9% vs 第2季(限制后)5.1%(OR=2.77;95%CI 0.98-7.8,p=0.045)。
- 未暴露于帕利珠单抗者RSVH第1季1.8% vs 第2季5.9%(OR=3.42;95%CI 0.96-12.20,p=0.045)。
- 其他呼吸道病毒住院发生率两季无差异。
- 作者认为,帕利珠单抗处方与报销规则决策应基于对成本效益比的审慎评估。
适用人群与场景
- 胎龄29至35周、2015年3月15日至2017年3月14日出生、在意大利北部三个新生儿重症监护病房(NICU)的婴儿。
- 632例合格婴儿中536例有数据(第1季262例、第2季274例)。
研究设计与关键结果
- 研究类型:非干预性回顾性队列研究,三个NICU,纳入胎龄29至35周婴儿,比较AIFA限制帕利珠单抗报销前后两个流行季。
- 总体RSVH:第1季(2015-2016)1.9% vs 第2季(2016-2017)5.1%(OR=2.77;95%CI 0.98-7.8,p=0.045)。
- 仅限未暴露于帕利珠单抗者:RSVH第1季1.8% vs 第2季5.9%(OR=3.42;95%CI 0.96-12.20,p=0.045)。
- 其他呼吸道病毒住院发生率两季无差异。
证据类型、等级与局限
- 证据类型:非干预性回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,限制帕利珠单抗报销资格(将胎龄>29周婴儿排除在外)导致RSVH显著增加,但未影响其他呼吸道病毒住院。
- 作者认为,未来帕利珠单抗处方与报销规则决策应基于对成本效益比的审慎评估。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Premature infants have the highest risk of being hospitalized with respiratory syncytial virus (RSV) infections. Palivizumab is the only licensed agent for RSVhospitalization (RSVH) prophylaxis in infants born at < 35 weeks of gestational age (wGA). In 2016, the Italian Drug Agency (Agenzia Italiana del Farmaco [AIFA]) has restricted the eligibility for reimbursement to infants at high risk of RSVH, ruling out palivizumab administration for infants born at > 29 wGA. The aim of the present study was to compare the incidence of RSVH in two consecutive epidemic seasons (2015-2016 vs. 2016-2017), that is, before and after the new AIFA recommendations on palivizumab eligibility.
STUDY DESIGN: This was a noninterventional retrospective cohort study conducted at three neonatal intensive care units (NICUs) in northern Italy. Infants born at 29 and 35 wGA between March 15, 2015 and March 14, 2017 were enrolled for this study. Electronic medical charts were reviewed and parents were interviewed by telephone. Data were collected on neonatal course during NICU stay, palivizumab administration, and hospitalizations related to respiratory infections during the 1st year of life, comparing the infants born in season 1 with season 2.
RESULTS: Of 632 eligible infants, data were available for 536 (262 in season 1 and 274 in season 2). Overall, RSVH occurred 1.9 and 5.1% in infants in seasons 1 and 2, respectively (odds ratio [OR] = 2.77; 95% confidence interval [CI]: 0.98-7.8, p = 0.045). When the analysis was limited to patients not exposed to palivizumab, RSVHs were recorded for 1.8 and 5.9% infants in seasons 1 and 2, respectively (OR = 3.42; 95% CI: 0.96-12.20, p = 0.045). It is noteworthy that the incidence of hospital admissions for respiratory viruses other than RSV did not differ between the two seasons.
CONCLUSION: Restricting eligibility for palivizumab reimbursement led to a significant increase in RSVH but had no impact on hospitalizations for other respiratory viruses. Future decisions on palivizumab prescription and coverage rules should be driven by a careful assessment of the cost-benefit ratio.
参考来源
- Priante E, Tavella E, Girardi E, et al. Restricted Palivizumab Recommendations and the Impact on RSV Hospitalizations among Infants Born at > 29 Weeks of Gestational Age: An Italian Multicenter Study. Am J Perinatol. 2019. PMID: 31238365. doi:10.1055/s-0039-1691771
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。